Eintrag weiter verarbeiten
Clinical and prognostic role of annexin A2 in multiple myeloma.
Gespeichert in:
| Veröffentlicht in: | Blood 120(2012), 5, Seite 1087-94 |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| Titel: | Clinical and prognostic role of annexin A2 in multiple myeloma./ Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
2012
|
| Gesamtaufnahme: |
: Blood, 120(2012), 5, Seite 1087-94
, volume:120 |
| Schlagwörter: | |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 04476caa a2200697 4500 | ||
|---|---|---|---|
| 001 | 0-157674275X | ||
| 003 | DE-627 | ||
| 005 | 20220814171910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180621s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood-2012-03-415588 |2 doi | |
| 035 | |a (DE-627)157674275X | ||
| 035 | |a (DE-576)50674275X | ||
| 035 | |a (DE-599)BSZ50674275X | ||
| 035 | |a (OCoLC)1341012179 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seckinger, Anja |d 1980- |e VerfasserIn |0 (DE-588)134177371 |0 (DE-627)562118225 |0 (DE-576)278603734 |4 aut | |
| 245 | 1 | 0 | |a Clinical and prognostic role of annexin A2 in multiple myeloma. |c Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose |
| 264 | 1 | |c 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Prepublished online June 15, 2012 | ||
| 500 | |a Gesehen am 21.06.2018 | ||
| 520 | |a Annexin A2 (ANXA2) promotes myeloma cell growth, reduces apoptosis in myeloma cell lines, and increases osteoclast formation. ANXA2 has been described in small cohorts of samples as expressed by myeloma cells and cells of the BM microenvironment. To investigate its clinical role, we assessed 1148 samples including independent cohorts of 332 and 701 CD138-purified myeloma cell samples from previously untreated patients together with clinical prognostic factors, chromosomal aberrations, and gene expression-based high-risk scores, along with expression of ANXA2 in whole BM samples, stromal cells, osteoblasts, osteoclasts, and BM sera. ANXA2 is expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in myeloma cells is associated with significantly inferior event-free and overall survival independently of conventional prognostic factors and is associated with gene expression-determined high risk and high proliferation. Within the BM, all cell populations, including osteoblasts, osteoclasts, and stromal cells, express ANXA2. ANXA2 expression is increased significantly in myelomatous versus normal BM serum. ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients. | ||
| 650 | 4 | |a multiple | |
| 650 | 4 | |a myeloma | |
| 700 | 1 | |a Meißner, Tobias |e VerfasserIn |0 (DE-588)1014101379 |0 (DE-627)705167224 |0 (DE-576)348311613 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Hose, Katja |e VerfasserIn |0 (DE-588)1161566651 |0 (DE-627)1024854140 |0 (DE-576)506742016 |4 aut | |
| 700 | 1 | |a Jauch, Anna |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Ewerbeck, Volker |d 1950- |e VerfasserIn |0 (DE-588)172066190 |0 (DE-627)696972069 |0 (DE-576)132940264 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 120(2012), 5, Seite 1087-94 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2012 |g number:5 |g pages:1087-94 |g extent:8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood-2012-03-415588 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://www.hal.inserm.fr/inserm-00726994 |x Verlag |z kostenfrei |3 Volltext |
| 936 | u | w | |d 120 |j 2012 |e 5 |h 1087-94 |g 8 |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood-2012-03-415588 |9 LFER |
| 852 | |a LFER |z 2018-07-10T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Meissner, Tobias | ||
| 900 | |a Hose, D. | ||
| 900 | |a Goldschmidt, H. | ||
| 900 | |a Goldschimdt, Hartmut | ||
| 900 | |a Goldschmidt, Harmut | ||
| 900 | |a Hillengass, Jens | ||
| 900 | |a Hillengass, J. | ||
| 900 | |a Jauch, A. | ||
| 900 | |a Ewerbeck, V. | ||
| 900 | |a Seckinger, A. | ||
| 951 | |b XA-DE | ||
| 980 | |a 157674275X |b 0 |k 157674275X |o 50674275X |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Clinical+and+prognostic+role+of+annexin+A2+in+multiple+myeloma&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Seckinger%2C+Anja&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1528-0020 |
|---|
| _version_ | 1757949675823955968 |
|---|---|
| access_facet | Electronic Resources |
| author | Seckinger, Anja, Meißner, Tobias, Hillengaß, Jens, Hose, Katja, Jauch, Anna, Ewerbeck, Volker, Goldschmidt, Hartmut, Hose, Dirk |
| author_facet | Seckinger, Anja, Meißner, Tobias, Hillengaß, Jens, Hose, Katja, Jauch, Anna, Ewerbeck, Volker, Goldschmidt, Hartmut, Hose, Dirk |
| author_role | aut, aut, aut, aut, aut, aut, aut, aut |
| author_sort | Seckinger, Anja 1980- |
| author_variant | a s as, t m tm, j h jh, k h kh, a j aj, v e ve, h g hg, d h dh |
| callnumber-sort | |
| collection | lfer |
| container_reference | 120(2012), 5, Seite 1087-94 |
| container_title | Blood |
| contents | Annexin A2 (ANXA2) promotes myeloma cell growth, reduces apoptosis in myeloma cell lines, and increases osteoclast formation. ANXA2 has been described in small cohorts of samples as expressed by myeloma cells and cells of the BM microenvironment. To investigate its clinical role, we assessed 1148 samples including independent cohorts of 332 and 701 CD138-purified myeloma cell samples from previously untreated patients together with clinical prognostic factors, chromosomal aberrations, and gene expression-based high-risk scores, along with expression of ANXA2 in whole BM samples, stromal cells, osteoblasts, osteoclasts, and BM sera. ANXA2 is expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in myeloma cells is associated with significantly inferior event-free and overall survival independently of conventional prognostic factors and is associated with gene expression-determined high risk and high proliferation. Within the BM, all cell populations, including osteoblasts, osteoclasts, and stromal cells, express ANXA2. ANXA2 expression is increased significantly in myelomatous versus normal BM serum. ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients. |
| ctrlnum | (DE-627)157674275X, (DE-576)50674275X, (DE-599)BSZ50674275X, (OCoLC)1341012179 |
| doi_str_mv | 10.1182/blood-2012-03-415588 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0021171722 |
| footnote | Prepublished online June 15, 2012, Gesehen am 21.06.2018 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | Germany |
| hierarchy_parent_id | 0-266886647 |
| hierarchy_parent_title | Blood |
| hierarchy_sequence | 120(2012), 5, Seite 1087-94 |
| hierarchy_top_id | 0-266886647 |
| hierarchy_top_title | Blood |
| id | 0-157674275X |
| illustrated | Not Illustrated |
| imprint | 2012 |
| imprint_str_mv | 2012 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-157674275X |
| is_hierarchy_title | Clinical and prognostic role of annexin A2 in multiple myeloma. |
| isil_str_mv | LFER |
| issn | 1528-0020 |
| kxp_id_str | 157674275X |
| language | English |
| last_indexed | 2023-02-16T01:37:34.905Z |
| local_heading_facet_dezwi2 | multiple, myeloma |
| marc024a_ct_mv | 10.1182/blood-2012-03-415588 |
| match_str | seckinger2012clinicalandprognosticroleofannexina2inmultiplemyeloma |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 075961938 |
| multipart_part | (075961938)120(2012), 5, Seite 1087-94 |
| names_id_str_mv | (DE-588)134177371, (DE-627)562118225, (DE-576)278603734, (DE-588)1014101379, (DE-627)705167224, (DE-576)348311613, (DE-588)124918549, (DE-627)368073823, (DE-576)294568298, (DE-588)1161566651, (DE-627)1024854140, (DE-576)506742016, (DE-588)1025525140, (DE-627)722525362, (DE-576)168357496, (DE-588)172066190, (DE-627)696972069, (DE-576)132940264, (DE-588)102258023X, (DE-627)717003809, (DE-576)365637386, (DE-588)139824995, (DE-627)613790308, (DE-576)313431698 |
| oclc_num | 1341012179 |
| physical | 8 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 50674275X |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Seckinger, Anja 1980- VerfasserIn (DE-588)134177371 (DE-627)562118225 (DE-576)278603734 aut, Clinical and prognostic role of annexin A2 in multiple myeloma. Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose, 2012, 8, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Prepublished online June 15, 2012, Gesehen am 21.06.2018, Annexin A2 (ANXA2) promotes myeloma cell growth, reduces apoptosis in myeloma cell lines, and increases osteoclast formation. ANXA2 has been described in small cohorts of samples as expressed by myeloma cells and cells of the BM microenvironment. To investigate its clinical role, we assessed 1148 samples including independent cohorts of 332 and 701 CD138-purified myeloma cell samples from previously untreated patients together with clinical prognostic factors, chromosomal aberrations, and gene expression-based high-risk scores, along with expression of ANXA2 in whole BM samples, stromal cells, osteoblasts, osteoclasts, and BM sera. ANXA2 is expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in myeloma cells is associated with significantly inferior event-free and overall survival independently of conventional prognostic factors and is associated with gene expression-determined high risk and high proliferation. Within the BM, all cell populations, including osteoblasts, osteoclasts, and stromal cells, express ANXA2. ANXA2 expression is increased significantly in myelomatous versus normal BM serum. ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients., multiple, myeloma, Meißner, Tobias VerfasserIn (DE-588)1014101379 (DE-627)705167224 (DE-576)348311613 aut, Hillengaß, Jens 1974- VerfasserIn (DE-588)124918549 (DE-627)368073823 (DE-576)294568298 aut, Hose, Katja VerfasserIn (DE-588)1161566651 (DE-627)1024854140 (DE-576)506742016 aut, Jauch, Anna VerfasserIn (DE-588)1025525140 (DE-627)722525362 (DE-576)168357496 aut, Ewerbeck, Volker 1950- VerfasserIn (DE-588)172066190 (DE-627)696972069 (DE-576)132940264 aut, Goldschmidt, Hartmut 1956- VerfasserIn (DE-588)102258023X (DE-627)717003809 (DE-576)365637386 aut, Hose, Dirk 1969- VerfasserIn (DE-588)139824995 (DE-627)613790308 (DE-576)313431698 aut, Enthalten in Blood Washington, DC : American Society of Hematology, 1946 120(2012), 5, Seite 1087-94 Online-Ressource (DE-627)266886647 (DE-600)1468538-3 (DE-576)075961938 1528-0020 nnns, volume:120 year:2012 number:5 pages:1087-94 extent:8, http://dx.doi.org/10.1182/blood-2012-03-415588 Verlag Resolving-System kostenfrei Volltext, http://www.hal.inserm.fr/inserm-00726994 Verlag kostenfrei Volltext, http://dx.doi.org/10.1182/blood-2012-03-415588 LFER, LFER 2018-07-10T00:00:00Z |
| spellingShingle | Seckinger, Anja, Meißner, Tobias, Hillengaß, Jens, Hose, Katja, Jauch, Anna, Ewerbeck, Volker, Goldschmidt, Hartmut, Hose, Dirk, Clinical and prognostic role of annexin A2 in multiple myeloma, Annexin A2 (ANXA2) promotes myeloma cell growth, reduces apoptosis in myeloma cell lines, and increases osteoclast formation. ANXA2 has been described in small cohorts of samples as expressed by myeloma cells and cells of the BM microenvironment. To investigate its clinical role, we assessed 1148 samples including independent cohorts of 332 and 701 CD138-purified myeloma cell samples from previously untreated patients together with clinical prognostic factors, chromosomal aberrations, and gene expression-based high-risk scores, along with expression of ANXA2 in whole BM samples, stromal cells, osteoblasts, osteoclasts, and BM sera. ANXA2 is expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in myeloma cells is associated with significantly inferior event-free and overall survival independently of conventional prognostic factors and is associated with gene expression-determined high risk and high proliferation. Within the BM, all cell populations, including osteoblasts, osteoclasts, and stromal cells, express ANXA2. ANXA2 expression is increased significantly in myelomatous versus normal BM serum. ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients., multiple, myeloma |
| swb_id_str | 50674275X |
| title | Clinical and prognostic role of annexin A2 in multiple myeloma |
| title_auth | Clinical and prognostic role of annexin A2 in multiple myeloma. |
| title_full | Clinical and prognostic role of annexin A2 in multiple myeloma. Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose |
| title_fullStr | Clinical and prognostic role of annexin A2 in multiple myeloma. Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose |
| title_full_unstemmed | Clinical and prognostic role of annexin A2 in multiple myeloma. Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose |
| title_in_hierarchy | Clinical and prognostic role of annexin A2 in multiple myeloma. / Anja Seckinger, Tobias Meiβner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose, |
| title_short | Clinical and prognostic role of annexin A2 in multiple myeloma. |
| title_sort | clinical and prognostic role of annexin a2 in multiple myeloma |
| topic | multiple, myeloma |
| topic_facet | multiple, myeloma |
| url | http://dx.doi.org/10.1182/blood-2012-03-415588, http://www.hal.inserm.fr/inserm-00726994 |